Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 24 papers were listed this time. Here's a handful:
Lynch FL, Dickerson JF, Clarke G, et al. Incremental Cost-effectiveness of Combined Therapy vs Medication Only for Youth With Selective Serotonin Reuptake Inhibitor-Resistant Depression: Treatment of SSRI-Resistant Depression in Adolescents Trial Findings. Arch Gen Psychiatry. 2011 Mar;68(3):253-62. PubMed PMID: 21383263.
Schipper LG, Kievit W, den Broeder AA, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford). 2011 Mar 2. [Epub ahead of print] PubMed PMID: 21371999.
Brändle M, Azoulay M, Greiner RA. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin Pharmacol Ther. 2011 Mar;49(3):217-30. PubMed PMID: 21329624.
Grosso AM, Bodalia PN, Macallister RJ, et al. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Int J Clin Pract. 2011 Mar;65(3):253-63. Epub 2011 Feb 1. PubMed PMID: 21284790.
Borgström F, Ström O, Kleman M, et al. Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporos Int. 2011 Mar;22(3):955-65. Epub 2010 Jun 8. PubMed PMID: 20532482.